secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-09-25T23:59:59+00:00
Accession:  0001731122-24-001482
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax Chairman resigns citing policy disputes; auditor EisnerAmper resigns
---------------------------------------------------------------------------

- Chairman Eric Floyd resigned Sept 20, 2024, disagreeing with salary cuts and elimination of D&O insurance.
- Floyd warned D&O elimination could expose directors/officers to personal liability and hurt retention.
- EisnerAmper resigned as auditor Sept 20, 2024; no accounting disagreements were reported.
- New auditor Bush & Associated CPA LLC engaged Sept 24, 2024, approved by Audit Committee and Board.
- EisnerAmper's prior audit reports included a going-concern explanatory paragraph for FY2022 and FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001482/0001731122-24-001482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001482/e5980_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-001482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer